Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.
Conroy T, Bosset JF, Etienne PL, Rio E, François É, Mesgouez-Nebout N, Vendrely V, Artignan X, Bouché O, Gargot D, Boige V, Bonichon-Lamichhane N, Louvet C, Morand C, de la Fouchardière C, Lamfichekh N, Juzyna B, Jouffroy-Zeller C, Rullier E, Marchal F, Gourgou S, Castan F, Borg C; Unicancer Gastrointestinal Group and Partenariat de Recherche en Oncologie Digestive (PRODIGE) Group. Conroy T, et al. Among authors: mesgouez nebout n. Lancet Oncol. 2021 May;22(5):702-715. doi: 10.1016/S1470-2045(21)00079-6. Epub 2021 Apr 13. Lancet Oncol. 2021. PMID: 33862000 Clinical Trial.
Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial.
Blanchard P, Faivre L, Lesaunier F, Salem N, Mesgouez-Nebout N, Deniau-Alexandre E, Rolland F, Ferrero JM, Houédé N, Mourey L, Théodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Davin JL, Habibian M, Culine S, Laplanche A, Fizazi K. Blanchard P, et al. Among authors: mesgouez nebout n. Int J Radiat Oncol Biol Phys. 2016 Jan 1;94(1):85-92. doi: 10.1016/j.ijrobp.2015.09.020. Epub 2015 Sep 25. Int J Radiat Oncol Biol Phys. 2016. PMID: 26576711 Clinical Trial.
Combination of Abiraterone Acetate, Prostate Bed Radiotherapy, and Luteinizing Hormone-releasing Hormone Agonists in Biochemically Relapsing Patients After Prostatectomy (CARLHA): A Phase 2 Clinical Trial.
Ah-Thiane L, Campion L, Allouache N, Meyer E, Pommier P, Mesgouez-Nebout N, Serre AA, Créhange G, Guimas V, Rio E, Sargos P, Ladoire S, Mahier Ait Oukhatar C, Supiot S. Ah-Thiane L, et al. Among authors: mesgouez nebout n. Eur Urol Oncol. 2024 May 10:S2588-9311(24)00108-1. doi: 10.1016/j.euo.2024.04.014. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38734543
[Esophageal cancer: outcome according to therapeutic strategy].
Rousseau D, Capitain O, Denis F, Girault S, Poirier AL, Paumier A, Cellier P, Hamy A, Mahé MA, Mesgouez-Nebout N. Rousseau D, et al. Cancer Radiother. 2013 Feb;17(1):10-20. doi: 10.1016/j.canrad.2012.10.011. Epub 2012 Dec 25. Cancer Radiother. 2013. PMID: 23270680 French.
[Adjuvant treatment of keloid scars: electrons or brachytherapy?].
Yossi S, Krhili S, Mesgouez-Nebout N, Vinchon-Petit S, Jadaud E, Tuchais C, Cellier P, Autret D, Rio E, Fernandez L, Poirier AL, Mahé MA, Paumier A. Yossi S, et al. Cancer Radiother. 2013 Feb;17(1):21-5. doi: 10.1016/j.canrad.2012.11.002. Epub 2013 Jan 14. Cancer Radiother. 2013. PMID: 23332126 French.
Cost and Toxicity Comparisons of Two IMRT Techniques for Prostate Cancer: A Micro-Costing Study and Weighted Propensity Score Analysis Based on a Prospective Study.
Masson I, Bellanger M, Perrocheau G, Mahé MA, Azria D, Pommier P, Mesgouez-Nebout N, Giraud P, Peiffert D, Chauvet B, Dudouet P, Salem N, Noël G, Khalifa J, Latorzeff I, Guérin-Charbonnel C, Supiot S. Masson I, et al. Among authors: mesgouez nebout n. Front Oncol. 2022 Jan 11;11:781121. doi: 10.3389/fonc.2021.781121. eCollection 2021. Front Oncol. 2022. PMID: 35087753 Free PMC article.
Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancer.
Masson I, Larriviere L, Mahé MA, Azria D, Pommier P, Mesgouez-Nebout N, Giraud P, Peiffert D, Chauvet B, Dudouet P, Salem N, Noël G, Khalifa J, Latorzeff I, Guérin-Charbonnel C, Supiot S. Masson I, et al. Among authors: mesgouez nebout n. Clin Transl Radiat Oncol. 2023 Nov 17;44:100702. doi: 10.1016/j.ctro.2023.100702. eCollection 2024 Jan. Clin Transl Radiat Oncol. 2023. PMID: 38111609 Free PMC article.
Fracture incidence after 3 years of aromatase inhibitor therapy.
Bouvard B, Soulié P, Hoppé E, Georgin-Mege M, Royer M, Mesgouez-Nebout N, Lassalle C, Cellier P, Jadaud E, Abadie-Lacourtoisie S, Tuchais C, Vinchon-Petit S, Audran M, Chappard D, Legrand E. Bouvard B, et al. Ann Oncol. 2014 Apr;25(4):843-847. doi: 10.1093/annonc/mdu008. Epub 2014 Mar 7. Ann Oncol. 2014. PMID: 24608193 Free article.
Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome.
Scholl S, Popovic M, de la Rochefordiere A, Girard E, Dureau S, Mandic A, Koprivsek K, Samet N, Craina M, Margan M, Samuels S, Zijlmans H, Kenter G, Hillemanns P, Dema S, Dema A, Malenkovic G, Djuran B, Floquet A, Garbay D, Guyon F, Colombo PE, Fabbro M, Kerr C, Ngo C, Lecuru F, Campo ERD, Coutant C, Marchal F, Mesgouez-Nebout N, Fourchotte V, Feron JG, Morice P, Deutsch E, Wimberger P, Classe JM, Gleeson N, von der Leyen H, Minsat M, Dubot C, Gestraud P, Kereszt A, Nagy I, Balint B, Berns E, Jordanova E, Saint-Jorre N, Savignoni A, Servant N, Hupe P, de Koning L, Fumoleau P, Rouzier R, Kamal M. Scholl S, et al. Among authors: mesgouez nebout n. EBioMedicine. 2019 May;43:253-260. doi: 10.1016/j.ebiom.2019.03.069. Epub 2019 Apr 2. EBioMedicine. 2019. PMID: 30952619 Free PMC article.
15 results